We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Are Medical Stocks Lagging McKesson (MCK) This Year?
Read MoreHide Full Article
Investors interested in Medical stocks should always be looking to find the best-performing companies in the group. McKesson (MCK - Free Report) is a stock that can certainly grab the attention of many investors, but do its recent returns compare favorably to the sector as a whole? Let's take a closer look at the stock's year-to-date performance to find out.
McKesson is one of 1175 companies in the Medical group. The Medical group currently sits at #7 within the Zacks Sector Rank. The Zacks Sector Rank considers 16 different sector groups. The average Zacks Rank of the individual stocks within the groups is measured, and the sectors are listed from best to worst.
The Zacks Rank emphasizes earnings estimates and estimate revisions to find stocks with improving earnings outlooks. This system has a long record of success, and these stocks tend to be on track to beat the market over the next one to three months. McKesson is currently sporting a Zacks Rank of #2 (Buy).
Over the past 90 days, the Zacks Consensus Estimate for MCK's full-year earnings has moved 0.1% higher. This means that analyst sentiment is stronger and the stock's earnings outlook is improving.
Our latest available data shows that MCK has returned about 1% since the start of the calendar year. At the same time, Medical stocks have lost an average of 0.9%. This means that McKesson is outperforming the sector as a whole this year.
Annovis Bio, Inc. (ANVS - Free Report) is another Medical stock that has outperformed the sector so far this year. Since the beginning of the year, the stock has returned 23%.
For Annovis Bio, Inc. the consensus EPS estimate for the current year has increased 12% over the past three months. The stock currently has a Zacks Rank #2 (Buy).
Looking more specifically, McKesson belongs to the Medical - Dental Supplies industry, which includes 18 individual stocks and currently sits at #101 in the Zacks Industry Rank. Stocks in this group have gained about 4.9% so far this year, so MCK is slightly underperforming its industry this group in terms of year-to-date returns.
On the other hand, Annovis Bio, Inc. belongs to the Medical - Biomedical and Genetics industry. This 557-stock industry is currently ranked #91. The industry has moved +1.5% year to date.
Investors interested in the Medical sector may want to keep a close eye on McKesson and Annovis Bio, Inc. as they attempt to continue their solid performance.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Are Medical Stocks Lagging McKesson (MCK) This Year?
Investors interested in Medical stocks should always be looking to find the best-performing companies in the group. McKesson (MCK - Free Report) is a stock that can certainly grab the attention of many investors, but do its recent returns compare favorably to the sector as a whole? Let's take a closer look at the stock's year-to-date performance to find out.
McKesson is one of 1175 companies in the Medical group. The Medical group currently sits at #7 within the Zacks Sector Rank. The Zacks Sector Rank considers 16 different sector groups. The average Zacks Rank of the individual stocks within the groups is measured, and the sectors are listed from best to worst.
The Zacks Rank emphasizes earnings estimates and estimate revisions to find stocks with improving earnings outlooks. This system has a long record of success, and these stocks tend to be on track to beat the market over the next one to three months. McKesson is currently sporting a Zacks Rank of #2 (Buy).
Over the past 90 days, the Zacks Consensus Estimate for MCK's full-year earnings has moved 0.1% higher. This means that analyst sentiment is stronger and the stock's earnings outlook is improving.
Our latest available data shows that MCK has returned about 1% since the start of the calendar year. At the same time, Medical stocks have lost an average of 0.9%. This means that McKesson is outperforming the sector as a whole this year.
Annovis Bio, Inc. (ANVS - Free Report) is another Medical stock that has outperformed the sector so far this year. Since the beginning of the year, the stock has returned 23%.
For Annovis Bio, Inc. the consensus EPS estimate for the current year has increased 12% over the past three months. The stock currently has a Zacks Rank #2 (Buy).
Looking more specifically, McKesson belongs to the Medical - Dental Supplies industry, which includes 18 individual stocks and currently sits at #101 in the Zacks Industry Rank. Stocks in this group have gained about 4.9% so far this year, so MCK is slightly underperforming its industry this group in terms of year-to-date returns.
On the other hand, Annovis Bio, Inc. belongs to the Medical - Biomedical and Genetics industry. This 557-stock industry is currently ranked #91. The industry has moved +1.5% year to date.
Investors interested in the Medical sector may want to keep a close eye on McKesson and Annovis Bio, Inc. as they attempt to continue their solid performance.